The European Paediatric Psoriasis Research Network |
Management of difficult-to-treat paediatric psoriasis survey
Dear Colleague,
Paediatric psoriasis can be challenging to treat. Although paediatric and adolescent patients generally respond well to topical treatments, some experience inadequate disease control requiring second line agents including phototherapy, systemic therapies (some are used off label) or biological agents. The management differs between European countries and the aim of this study is to identify these differences with respect to managing common difficult-to-treat subtypes of psoriasis in children.
The same questionnaire will be distributed in many European countries to paediatric dermatologists.
Paediatric psoriasis can be challenging to treat. Although paediatric and adolescent patients generally respond well to topical treatments, some experience inadequate disease control requiring second line agents including phototherapy, systemic therapies (some are used off label) or biological agents. The management differs between European countries and the aim of this study is to identify these differences with respect to managing common difficult-to-treat subtypes of psoriasis in children.
The same questionnaire will be distributed in many European countries to paediatric dermatologists.
Your opinion is very important to us.
Thank you very much for taking time to complete this questionnaire. It consists of a series of five cases and asks clinicians to select which treatments they would use first and second line. It will take approximately 15 minutes to complete.
United Kingdom: Dr Wedad Abdelrahman, Dr Sally Aziz, Dr Catherine Drislane and Prof Carsten Flohr, Guy’s and St Thomas’ Hospital; Dr Esther Burden-Teh, University of Nottingham; Prof Ruth Murphy, University of Sheffield; Dr Tess McPherson, Oxford University Hospitals, on behalf of British Society of Paediatric and Adolescent Dermatology
Thank you very much for taking time to complete this questionnaire. It consists of a series of five cases and asks clinicians to select which treatments they would use first and second line. It will take approximately 15 minutes to complete.
United Kingdom: Dr Wedad Abdelrahman, Dr Sally Aziz, Dr Catherine Drislane and Prof Carsten Flohr, Guy’s and St Thomas’ Hospital; Dr Esther Burden-Teh, University of Nottingham; Prof Ruth Murphy, University of Sheffield; Dr Tess McPherson, Oxford University Hospitals, on behalf of British Society of Paediatric and Adolescent Dermatology
France: Dr Emmanuel Mahé, Centre Hospitalier Victor Dupouy, Argenteuil, Société Française de Dermatologie Pédiatrique (SFDP), on behalf of Groupe de Recherche sur le Psoriasis (GrPso) de la Société Française de Dermatologie (SFD)
Italy: Dr Vito Di Lernia, Arcispedale Santa Maria Nuova, Reggio Emilia, on behalf of Società Italiana di Dermatologia Pediatrica (S.I.Der.P.)
